Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;17(6):770-773.
doi: 10.1513/AnnalsATS.201910-794RL.

Dyspnea and Inhaled Corticosteroid and Long-acting β-Agonist Therapy in an Occupational Cohort: A Longitudinal Study

Barbara Putman  1   2 , Lies Lahousse  2 , Ankura Singh  3   4 , Rachel Zeig-Owens  3   4 , Charles B Hall  4 , Melissa J Fazzari  4 , Theresa Schwartz  3   4 , Mayris P Webber  3   4 , Hillel W Cohen  4 , David J Prezant  3   4 , Michael D Weiden  1   3
Affiliations

Dyspnea and Inhaled Corticosteroid and Long-acting β-Agonist Therapy in an Occupational Cohort: A Longitudinal Study

Barbara Putman et al. Ann Am Thorac Soc. 2020 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Forest plot showing variables associated with being included in the study population and receiving inhaled corticosteroid (ICS)/long-acting β-agonist (LABA) treatment for longer than 2 years versus not receiving ICS/LABA treatment (n = 7,777). Results shown are from a multivariable logistic regression analysis performed to determine the associations between first post-9/11 medical monitoring data and ICS/LABA treatment for longer than 2 years (odds ratios and 95% confidence intervals [bars]); data are also adjusted for race. FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; mMRC = modified Medical Research Council dyspnea scale; WTC = World Trade Center.
Figure 2.
Figure 2.
Longitudinal modified Medical Research Council (mMRC) dyspnea scale scores and 95% confidence intervals in linear mixed effects models, stratified by responder type. mMRC scores were estimated using linear mixed effects models with random intercepts, with categorized year, age, body mass index, and race as fixed effects. The trajectory of the responder group is shown as a solid blue line, and the trajectory in the nonresponders is shown as a broken red line. (A) Trajectories of mMRC scores relative to September 11, 2001 (9/11). Nonresponders had a gradual rise in mMRC scores starting 11 years after WTC exposure, culminating in worse dyspnea score at the end of longitudinal follow-up. (B) Trajectories of mMRC scores relative to treatment initiation. Responders had a sharp increase in mMRC scores before treatment, followed by a subsequent decrease. Nonresponders, however, had a gradual rise in mMRC scores before treatment initiation, which continued to increase after inhaled corticosteroid/long-acting β-agonist (ICS/LABA) initiation.
See this image and copyright information in PMC

References

    1. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–639. - PMC - PubMed
    1. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405–1411. - PubMed
    1. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844. - PubMed
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
    1. Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, et al. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2018;13:3669–3676. - PMC - PubMed

Publication types

Substances